chronic hives
Novartis Receives FDA Approval for Rhapsido: First Oral BTK Inhibitor for Chronic Hives
Novartis; Rhapsido; FDA approval; Bruton’s tyrosine kinase inhibitor (BTKi); remibrutinib; chronic spontaneous urticaria (CSU); chronic hives; immunology; oral therapy; competition
Celldexs anti-cKIT antibody proves it can reduce chronic hives in another phase 2 trial
Antibodies, Trial Phase, Urticaria, chronic hives